Sun Pharma Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

Sun Pharma CMP: Rs 1,793 (2026). 52W High: Rs 1,917. 52W Low: Rs 1,547. Mkt Cap: Rs 430,129 Cr. P/E: 143. Analyst Consensus Target: Rs 2,050.

The Sun Pharma stock prediction for 2026 from leading brokerages and research analysts covers a wide range that reflects the company’s sector dynamics, earnings trajectory and macro environment. The Sun Pharma stock prediction published in this article is sourced from publicly available research and may or may not be achieved. Investors should treat any Sun Pharma share price prediction as one data point and not as a guarantee of future performance.

Interest in the Sun Pharma stock forecast for 2026 has grown as investors look for anchor points in a volatile market. This article reviews every dimension of the Sun Pharma stock prediction that analysts are tracking, including key business drivers, bull and bear scenarios and the primary risks that could shift the Sun Pharma share price prediction in either direction. The analyst consensus for 2026 should be verified with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

What Analysts Predict for Sun Pharma Stock in 2026

Analyst consensus on the Sun Pharma stock prediction for 2026 is tracked by leading brokerages and research firms. The table below shows the latest available Sun Pharma stock forecast data from CLSA and Morgan Stanley. All Sun Pharma share price prediction figures are sourced from publicly available research and should be verified against the most current brokerage reports before publishing.

The Sun Pharma stock prediction range from the analyst community reflects a genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. Each Sun Pharma share price prediction from an individual brokerage should be read alongside the stated assumptions. The implied upside in the Sun Pharma stock forecast from the current market price of Rs 1,793 may or may not be realised by the end of 2026.

Sun Pharma Company Overview

Sun Pharmaceutical Industries is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Sun Pharma stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk. Understanding this context is the starting point for any Sun Pharma stock prediction and helps investors assess whether the analyst Sun Pharma stock forecast is grounded in a realistic view of the company’s competitive position.

Sun Pharma Stock Prediction by Time Horizon

Analysts split the Sun Pharma share price prediction across different time frames because the variables that drive the short-term view are very different from those that shape a 3 to 5 year outlook. The following three horizons give a structured way to think about the range of analyst estimates for 2026 and beyond.

Short-Term Sun Pharma Stock Prediction (1 to 3 Months)

The near-term analyst view on Sun Pharmaceutical Industries reflects current market sentiment, sector news flow and upcoming earnings data points. Analysts forming a short-term Sun Pharma stock forecast are watching key support and resistance levels around the current market price of Rs 1,793. A Sun Pharma share price prediction in the near term is the most uncertain of all time horizons and may or may not hold as new information emerges.

12-Month Sun Pharma Stock Prediction

The 12 month Sun Pharma stock prediction from leading brokerages represents the most widely cited analyst consensus for the full-year 2026 outlook. CLSA has set a target of Rs 2,100 (Buy) while Morgan Stanley has set a target of Rs 2,000 (Overweight). Most research desks refresh their Sun Pharma stock forecast within two to four weeks of each quarterly earnings print. The Sun Pharma share price prediction should be verified against the most recent analyst reports before being used as an investment reference.

Long-Term Sun Pharma Stock Prediction

The long-term Sun Pharma stock prediction, built on a 3 to 5 year view, is based on assumptions about demand recovery, margin expansion and revenue diversification. Analysts who set a higher long-term Sun Pharma stock forecast cite the company’s structural growth drivers in the Pharmaceuticals and Healthcare sector. The long-term Sun Pharma share price prediction should be treated as a directional indicator and may or may not prove accurate over the forecast period.

Sun Pharma Stock Forecast: Key Factors Behind the Prediction

Understanding what drives the Sun Pharma stock forecast requires reviewing the variables that most analysts reference when forming their Sun Pharma share price prediction for 2026. The following four factors appear consistently in research reports on the Sun Pharma stock prediction and are the primary inputs into the bull and bear case scenarios.

US Generic Revenue

US generics revenue is the most watched metric in the Sun Pharma stock forecast. USFDA approval timelines and price erosion rates directly affect the Sun Pharma share price prediction from most research desks.

Domestic Formulations Growth

Domestic formulation growth provides a stable base that supports the Sun Pharma stock prediction even when export growth faces headwinds.

R&D Pipeline

The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Sun Pharma share price prediction. New product approvals are cited as catalysts for the Sun Pharma stock prediction.

EBITDA Margin

Sustained EBITDA margin expansion is typically the basis for the bullish Sun Pharma stock forecast. Margin recovery strengthens the Sun Pharma share price prediction from most research desks.

Sun Pharma Stock Prediction: Bull and Bear Scenarios

Any complete Sun Pharma share price prediction must account for both positive and negative outcomes. The following scenarios are built from analyst commentary and sector data, representing the range of the Sun Pharma stock prediction rather than a fresh estimate from Univest.

The bull case Sun Pharma stock forecast assumes most positive variables converge simultaneously. The bear case Sun Pharma share price prediction reflects a scenario where demand deteriorates and the sector de-rates below current multiples. The base case Sun Pharma stock prediction represents the analyst consensus view of Rs 2,050, which may or may not prove accurate.

How Analysts Are Reading the Sun Pharma Stock Story

Analyst reviews of the Sun Pharma share price prediction consistently highlight two opposing forces in 2026. The positive case for the Sun Pharma stock forecast rests on the company’s core business strengths in the Pharmaceuticals and Healthcare sector, including competitive position and potential for margin or volume improvement over the next four quarters.

The cautious side of the analyst view points to near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Analysts who maintain a conservative Sun Pharma stock prediction cite these as the primary reasons for staying neutral or cautious on the stock. Many research desks have revised their view since the start of 2026 as macro data evolved.

Overall, the Sun Pharma stock prediction consensus from the analyst community is built on real business strengths set against real risks. Investors should read the full Sun Pharma stock forecast report from each brokerage, including assumptions and risk disclosures, before using any Sun Pharma share price prediction as an investment reference.

Key Risks That Could Change the Sun Pharma Stock Prediction

Any Sun Pharma share price prediction carries risks that could shift the Sun Pharma stock forecast materially in either direction. Investors should review these risks before acting on any Sun Pharma stock prediction from an analyst or research desk.

USFDA Regulatory Risk

Import alerts and warning letters from the USFDA are the most significant risks to the Sun Pharma stock prediction. A facility closure would force an immediate sharp revision to the Sun Pharma share price prediction.

Price Erosion in the US

Pricing pressure in US generics compresses the revenue per product and affects the Sun Pharma stock forecast. Aggressive price erosion pushes the Sun Pharma share price prediction toward the bear case.

R&D Execution Risk

Delays in clinical trials or approval failures affect the Sun Pharma stock prediction. The Sun Pharma share price prediction is particularly sensitive to key pipeline asset announcements.

Currency Risk

A strengthening rupee against the dollar reduces export realisation and affects the Sun Pharma stock forecast. Currency risk is embedded in conservative Sun Pharma share price prediction models.

How to Monitor the Sun Pharma Stock Forecast and Make Decisions

Check Live Sun Pharma Fundamentals on the Univest Screener

Start by opening a demat account with a SEBI registered broker if you do not already have one. Before acting on any Sun Pharma share price prediction, ensure you understand the risks involved in equity investing.

Track the Sun Pharma stock prediction consensus quarterly: after every earnings release, most brokerages revise their Sun Pharma stock forecast within two weeks. Comparing the revised Sun Pharma stock prediction to the previous estimate tells you whether analyst sentiment on the stock is improving or deteriorating.

Compare the current market price of Rs 1,793 with the analyst target range of Rs 2,100 to Rs 2,000. The Sun Pharma share price prediction band can be wide, so position size should reflect that uncertainty.

Review the Sun Pharma stock prediction every quarter against the key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many.

Download the Univest iOS App or Univest Android App to track the live Sun Pharma stock prediction and Sun Pharma share price prediction changes in real time.

Conclusion

The Sun Pharma stock prediction for 2026 reflects the analyst community’s assessment of Sun Pharmaceutical Industries’s competitive position, earnings trajectory and macro environment. CLSA sets a Buy target of Rs 2,100 while Morgan Stanley has a Overweight target of Rs 2,000, giving an analyst consensus of Rs 2,050. The Sun Pharma stock forecast is set against near-term risks that make the Sun Pharma share price prediction range wide. Any estimate should be verified with the latest brokerage reports and does not constitute investment advice from Univest.

The analyst forecast will be revised after every quarterly result. Track the latest Sun Pharma stock prediction and Sun Pharma share price prediction changes on the Univest Screener and app to stay updated as 2026 progresses.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Frequently Asked Questions on Sun Pharma Stock Prediction 2026

What is the Sun Pharma stock prediction for 2026?

Ans. The Sun Pharma stock prediction for 2026 is based on analyst consensus from leading brokerages including CLSA and Morgan Stanley. The Sun Pharma share price prediction range reflects the company’s fundamentals, sector outlook and macro environment. All estimates are analyst views and may or may not be achieved.

Is the Sun Pharma stock prediction bullish or bearish?

Ans. The Sun Pharma stock prediction for 2026 is divided, with CLSA maintaining a Buy stance with a target of Rs 2,100. The Sun Pharma stock forecast consensus points to potential movement from current levels, though the Sun Pharma share price prediction range is wide, reflecting macro uncertainty.

What is the Sun Pharma share price prediction based on fundamentals?

Ans. The Sun Pharma share price prediction built on fundamentals considers the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking the Sun Pharma stock forecast closely cite these variables as the primary drivers of the 2026 outlook. Each analyst estimate may or may not reflect actual future performance.

What is the long-term Sun Pharma stock prediction?

Ans. The long-term Sun Pharma stock prediction is built around the assumption that the company’s core business drivers sustain over a multi-year horizon. Analysts with a higher Sun Pharma stock forecast point to demand recovery, margin improvement and revenue diversification. The long-term estimate carries more uncertainty than the 12-month consensus of Rs 2,050.

What are the key risks to the Sun Pharma stock prediction?

Ans. The key risks to the Sun Pharma stock prediction in 2026 include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Analysts who set a lower Sun Pharma share price prediction cite these as the primary downside risks. Every estimate should be read alongside its stated risk assumptions.

What does the Sun Pharma stock forecast say for 2026?

Ans. The Sun Pharma stock forecast for 2026 reflects a cautiously positive analyst consensus based on the company’s fundamental strengths. CLSA has a Buy rating with a target of Rs 2,100 while Morgan Stanley has a Overweight rating with a target of Rs 2,000. These Sun Pharma share price prediction estimates may or may not prove accurate.

Where can I track the latest Sun Pharma stock prediction?

Ans. You can track the latest Sun Pharma stock prediction, live price and fundamentals on the official NSE and BSE websites and on the Univest app and screener, alongside every updated Sun Pharma share price prediction and stock forecast from the analyst community.